Slow acting medications for progressive and painful knee osteoarthritis. How do we assess the benefit to risk of these potentially novel therapies?
作者信息
Lane Nancy E, Simon Lee S, Tambiah Jeyanesh
机构信息
Department of Medicine, U.C. Davis Health, Sacramento, CA, 95817, USA.
SDG, LLC, One Mifflin Place, Suite 400, Cambridge, MA, 02138, USA.
出版信息
Osteoarthr Cartil Open. 2024 Nov 27;7(1):100546. doi: 10.1016/j.ocarto.2024.100546. eCollection 2025 Mar.
Abstract
摘要
相似文献
1
Slow acting medications for progressive and painful knee osteoarthritis. How do we assess the benefit to risk of these potentially novel therapies?用于进行性疼痛性膝关节骨关节炎的慢效药物。我们如何评估这些潜在新疗法的获益与风险？
Osteoarthr Cartil Open. 2024 Nov 27;7(1):100546. doi: 10.1016/j.ocarto.2024.100546. eCollection 2025 Mar.
2
Association of Pharmacological Treatments With Long-term Pain Control in Patients With Knee Osteoarthritis: A Systematic Review and Meta-analysis.药物治疗与膝骨关节炎患者长期疼痛控制的相关性：系统评价和荟萃分析。
JAMA. 2018 Dec 25;320(24):2564-2579. doi: 10.1001/jama.2018.19319.
3
Comprehensive Review of Knee Osteoarthritis Pharmacological Treatment and the Latest Professional Societies' Guidelines.膝关节骨关节炎药物治疗及专业学会最新指南的综合综述
Pharmaceuticals (Basel). 2021 Mar 2;14(3):205. doi: 10.3390/ph14030205.
4
Procedural Treatments for Knee Osteoarthritis: A Review of Current Injectable Therapies.膝关节骨关节炎的程序性治疗：当前可注射疗法综述
Pain Res Manag. 2020 Feb 18;2020:3873098. doi: 10.1155/2020/3873098. eCollection 2020.
5
Association of leg-length inequality with knee osteoarthritis: a cohort study.腿长差异与膝骨关节炎的关联：一项队列研究。
Ann Intern Med. 2010 Mar 2;152(5):287-95. doi: 10.7326/0003-4819-152-5-201003020-00006.
6
State-of-the-Art management of knee osteoarthritis.膝关节骨关节炎的最新管理方法
World J Clin Cases. 2015 Feb 16;3(2):89-101. doi: 10.12998/wjcc.v3.i2.89.
7
Comments on the discordant recommendations for the use of symptomatic slow-acting drugs in knee osteoarthritis.关于膝骨关节炎中使用症状性慢作用药物的不一致推荐意见的评论
Curr Med Res Opin. 2015 May;31(5):1041-5. doi: 10.1185/03007995.2015.1027183. Epub 2015 Mar 24.
8
Adjunctive therapies in addition to land-based exercise therapy for osteoarthritis of the hip or knee.辅助疗法联合陆地运动疗法治疗髋或膝关节骨关节炎。
Cochrane Database Syst Rev. 2022 Oct 17;10(10):CD011915. doi: 10.1002/14651858.CD011915.pub2.
9
Is muscle strength in a painful limb affected by knee pain status of the contralateral limb? - Data from the Osteoarthritis Initiative.疼痛肢体的肌肉力量是否受对侧肢体膝关节疼痛状况的影响？——来自骨关节炎倡议组织的数据。
Ann Anat. 2019 Jan;221:68-75. doi: 10.1016/j.aanat.2018.08.003. Epub 2018 Sep 18.
10
Multisite Musculoskeletal Pain Is Associated with Long-Term Declined Physical Quality of Life and Knee-Related Quality of Life in Older Adults with or at Risk of Knee Osteoarthritis.多部位肌肉骨骼疼痛与老年膝骨关节炎患者或有膝关节骨关节炎风险患者的长期身体质量下降和膝关节相关生活质量下降有关。
Medicina (Kaunas). 2024 Aug 12;60(8):1305. doi: 10.3390/medicina60081305.
本文引用的文献
1
Structure-Guided Discovery of Potent and Selective CLK2 Inhibitors for the Treatment of Knee Osteoarthritis.基于结构的强效和选择性 CLK2 抑制剂的发现，用于治疗膝骨关节炎。
J Med Chem. 2024 Mar 28;67(6):4603-4623. doi: 10.1021/acs.jmedchem.3c02092. Epub 2024 Mar 18.
2
Preclinical Use of FGF-18 Augmentation for Improving Cartilage Healing Following Surgical Repair: A Systematic Review.FGF-18 增强在手术修复后改善软骨愈合的临床前应用：系统评价。
Cartilage. 2023 Mar;14(1):59-66. doi: 10.1177/19476035221142010. Epub 2022 Dec 21.
3
The Role of Interleukin-4 and Interleukin-10 in Osteoarthritic Joint Disease: A Systematic Narrative Review.白细胞介素-4 和白细胞介素-10 在骨关节炎性关节疾病中的作用：系统叙述性综述。
Cartilage. 2022 Apr-Jun;13(2):19476035221098167. doi: 10.1177/19476035221098167.
4
Prevalence Trends of Site-Specific Osteoarthritis From 1990 to 2019: Findings From the Global Burden of Disease Study 2019.1990 年至 2019 年特定部位骨关节炎的流行趋势：2019 年全球疾病负担研究的结果。
Arthritis Rheumatol. 2022 Jul;74(7):1172-1183. doi: 10.1002/art.42089. Epub 2022 Jun 2.
5
Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study.关节内注射 sprifermin 对膝骨关节炎患者的长期结构和症状影响：前瞻性研究的 5 年结果。
Ann Rheum Dis. 2021 Aug;80(8):1062-1069. doi: 10.1136/annrheumdis-2020-219181. Epub 2021 May 7.
6
A Phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis.一项 lorecivivint（一种新型关节内 CLK2/DYRK1A 抑制剂和 Wnt 通路调节剂）治疗膝骨关节炎的 2b 期随机临床试验。
Osteoarthritis Cartilage. 2021 May;29(5):654-666. doi: 10.1016/j.joca.2021.02.004. Epub 2021 Feb 12.
7
Diagnosis and Treatment of Hip and Knee Osteoarthritis: A Review.髋关节和膝关节骨关节炎的诊断与治疗：综述
JAMA. 2021 Feb 9;325(6):568-578. doi: 10.1001/jama.2020.22171.
8
Articular cartilage regeneration by activated skeletal stem cells.激活的骨骼干细胞实现关节软骨再生。
Nat Med. 2020 Oct;26(10):1583-1592. doi: 10.1038/s41591-020-1013-2. Epub 2020 Aug 17.
9
Targeted interleukin-10 plasmid DNA therapy in the treatment of osteoarthritis: Toxicology and pain efficacy assessments.靶向白细胞介素-10 质粒 DNA 治疗骨关节炎：毒理学和疼痛疗效评估。
Brain Behav Immun. 2020 Nov;90:155-166. doi: 10.1016/j.bbi.2020.08.005. Epub 2020 Aug 13.
10
Lorecivivint, a Novel Intraarticular CDC-like Kinase 2 and Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Treatment of Knee Osteoarthritis: A Phase II Randomized Trial.洛赛昔芬，一种新型关节内 CDC 样激酶 2 和双特异性酪氨酸磷酸化调节激酶 1A 抑制剂及 Wnt 通路调节剂，用于治疗膝骨关节炎：一项 II 期随机试验。
Arthritis Rheumatol. 2020 Oct;72(10):1694-1706. doi: 10.1002/art.41315. Epub 2020 Sep 6.
Zotero 插件